Genetically Elevated Apolipoprotein A-I, High-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
CONTEXT: Epidemiologically, levels of high-density lipoprotein (HDL) cholesterol and its major protein constituent, apolipoprotein A-I (apoA-I), are inversely related to risk of ischemic heart disease (IHD). OBJECTIVE: We tested whether common genetic variation in the apolipoprotein A1 gene (APOA1) contributes to apoA-I and HDL cholesterol levels and risk of IHD in the general population. DESIGN: We resequenced the regulatory and coding regions of APOA1 in 190 individuals from the Copenhagen City Heart Study with the lowest 1% (n=95) and highest 1% (n=95) apoA-I levels. Two single-nucleotide polymorphisms (SNPs) were subsequently genotyped in the Copenhagen City Heart Study (n=10,273) and in 2361 cases with IHD (the Copenhagen Ischemic Heart Disease Study). RESULTS: In total, 13 genetic variants were identified. Three SNPs, g.-560A→C, g.-151C→T, and *181A→G, determined a haplotype that differed between high and low apoA-I groups (6 vs. 1%, P=0.002). Genotype combinations of two SNPs, the g.-560A→C (tagging the g.-560A→C/g.-151C→T/*181A→G haplotype) and g.-310G→A (situated near a potential functional promoter site), were associated with increases in apoA-I and HDL cholesterol levels of up to 6.6 and 8.5%, respectively, resulting in theoretically predicted reductions in risk of 9 and 8% for IHD and 14 and 12% for myocardial infarction (MI). Despite this, these same genotype combinations were not associated with decreased risk of IHD or MI. CONCLUSION: Common genetic variation in APOA1 associated with increased apoA-I and HDL cholesterol levels did not associate with decreased risk of IHD or MI.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The causative role of HDL-C for protection against CVD has been questioned in several studies utilizing Mendelian randomization. 87,89,91,92”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [91]
In the citing paper
“The causative role of HDL-C for protection against CVD has been questioned in several studies utilizing Mendelian randomization.87,89,91,92”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [91]
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423 · cited 3×
“LDL cholesterol levels were calculated with the Friedewald equation if triglycerides were lower than 4 mmol/liter but measured directly at higher triglyceride levels (21).”
MethodInfluentialEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · cited 1×
“Furthermore, clinical trials have shown that cholesteryl ester transfer protein inhibition that raises HDL cholesterol increases coronary disease (38).”
BackgroundNordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058 · cited 1×
“We suggest that the observed atheroprotective effect of high levels of apoA-I and HDL cholesterol in epidemiological studies may not be due to the apoA-I and HDL elevation itself but may be caused by the concomitant reduction in levels of triglycerides and thus in atherogenic remnant lipoproteins (40).”
BackgroundSelf-citationNewly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585 · cited 1×
“Furthermore, neither candidate gene studies of APOA1 SNPs (15, 18) nor a genome-wide association study (39) has associated APOA1 SNPs with cardiovascular risk.”
BackgroundWalldius, G., Jungner, I., Holme, I., Aastveit, A. H., Kolar, W., & Steiner, E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07098-2 · Cited by 1,229
Multiple Rare Alleles Contribute to Low Plasma Levels of HDL Cholesterol
Cohen, J. C., Kiss, R. S., Pertsemlidis, A., Marcel, Y. L., McPherson, R., & Hobbs, H. H. (2004) · Science · doi:10.1126/science.1099870 · Cited by 1,108 · cited 1×
“This further supports the usefulness of the extreme group strategy for the detection of functionally important variants, as shown previously by us and others (2, 31).”
Clarke, R., Shipley, M., Lewington, S., Youngman, L., Collins, R., Marmot, M., & Peto, R. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010013 · Cited by 877 · cited 1×
“The theoretically predicted hazard ratios as a function of HDL cholesterol levels were corrected for regression dilution bias (24).”
BackgroundGenetically elevated C-reactive protein and ischemic vascular disease
Zacho, J., Tybjærg-Hansen, A., Jensen, J. S., Grande, P., Sillesen, H., & Nordestgaard, B. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707402 · Cited by 839
Self-citationMacrophage Reverse Cholesterol Transport: Key to the Regression of Atherosclerosis?
Cuchel, M., & Rader, D. J. (2006) · Circulation · doi:10.1161/circulationaha.104.475715 · Cited by 527
Cited by
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
“The causative role of HDL-C for protection against CVD has been questioned in several studies utilizing Mendelian randomization.(87,89,91,92) Recent studies suggest that HDL has a complex role in atherogenesis and that the presence of dysfunctional HDL may be more relevant to the ESC/EAS Guidelines 3016”
BackgroundCommon variants associated with plasma triglycerides and risk for coronary artery disease
Do, R., Willer, C. J., Schmidt, E. M., Sengupta, S., Gao, C., Peloso, G. M., Gustafsson, S., Kanoni, S., Ganna, A., Chen, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2795 · Cited by 862
Mendelian randomization of blood lipids for coronary heart disease
Holmes, M. V., Asselbergs, F. W., Palmer, T. M., Drenos, F., Lanktree, M. B., Nelson, C. P., Dale, C. E., Padmanabhan, S., Finan, C., Swerdlow, D. I., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/eht571 · Cited by 748
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Jørgensen, A. B., Frikke-Schmidt, R., West, A. S., Grande, P., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs431 · Cited by 501
Self-citationHigh-density lipoprotein revisited: biological functions and clinical relevance
von Eckardstein, A., Nordestgaard, B. G., Remaley, A. T., & Catapano, A. L. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac605 · Cited by 401
Genetics of Coronary Artery Disease
McPherson, R., & Tybjaerg-Hansen, A. (2016) · Circulation Research · doi:10.1161/circresaha.115.306566 · Cited by 371
“As noted above, MR studies have not supported a direct protective function of HDL cholesterol levels against CAD.”
BackgroundInfluentialSelf-citationHaase, C. L., Tybjærg-Hansen, A., Ali Qayyum, A., Schou, J., Nordestgaard, B. G., & Frikke-Schmidt, R. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1846 · Cited by 282
“(23) showed that by using the direct gene product of APOA1, apolipoprotein A-I in plasma, 3% of Caucasians with the lowest 1% apolipoprotein A-I levels”
BackgroundSelf-citationVegetarian or vegan diets and blood lipids: a meta-analysis of randomized trials
Koch, C. A., Kjeldsen, E. W., & Frikke-Schmidt, R. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad211 · Cited by 134
Self-citationHDL in Atherosclerotic Cardiovascular Disease: In Search of a Role
Casula, M., Colpani, O., Xie, S., Catapano, A. L., & Baragetti, A. (2021) · Cells · doi:10.3390/cells10081869 · Cited by 165
Benn, M., & Nordestgaard, B. G. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy045 · Cited by 130
A Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease
Ahmad, O. S., Morris, J. A., Mujammami, M., Forgetta, V., Leong, A., Li, R., Turgeon, M., Greenwood, C. M. T., Thanassoulis, G., Meigs, J. B., et al. (2015) · Nature Communications · doi:10.1038/ncomms8060 · Cited by 123
Lawlor, D. A., Nordestgaard, B. G., Benn, M., Zuccolo, L., Tybjaerg-Hansen, A., & Davey Smith, G. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht081 · Cited by 98
Self-citationManagement of residual risk after statin therapy
Reith, C. A., & Armitage, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.12.018 · Cited by 97
KONES, R. J. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37119 · Cited by 105
Plasma high-density lipoprotein cholesterol and risk of dementia: observational and genetic studies
Kjeldsen, E. W., Thomassen, J. Q., Rasmussen, I. J., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Frikke‐Schmidt, R. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab164 · Cited by 91
Self-citationGenetics, Dyslipidemia, and Cardiovascular Disease: New Insights
Stein, R., Ferrari, F., & Scolari, F. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1161-5 · Cited by 83
Ahmed, H. M., Miller, M. J., Nasir, K., McEvoy, J. W., Herrington, D. M., Blumenthal, R. S., & Blaha, M. J. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kwv305 · Cited by 90
“In contrast to these prior observational data, Mendelian randomized analyses of 54,000 participants showed that genetically lowHDL cholesterol levels were not associated with higher CHD risk and genetically high HDL cholesterol levels were not associated with lower CHD risk (23, 24).”
ResultCholesterol efflux capacity: An introduction for clinicians
Anastasius, M. O., Kockx, M., Jessup, W., SULLIVAN, D. R., Rye, K., & Kritharides, L. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.07.005 · Cited by 83
Karjalainen, M. K., Holmes, M. V., Wang, Q., Anufrieva, O., Kähönen, M., Lehtimäki, T., Havulinna, A. S., Kristiansson, K., Salomaa, V., Perola, M., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.02.002 · Cited by 73
HDL Cholesterol and Non-Cardiovascular Disease: A Narrative Review
Kjeldsen, E. W., Nordestgaard, L. T., & Frikke‐Schmidt, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094547 · Cited by 81
Self-citationLee, J., Chi, G., Fitzgerald, C., Kazmi, S. H. A., Kalaycı, A., Korjian, S., Duffy, D., Shaunik, A., Kingwell, B. A., Yeh, R. W., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.774418 · Cited by 77
HDL and Cardiovascular Risk: Time to Call the Plumber?
Hewing, B., Moore, K. J., & Fisher, E. A. A. (2012) · Circulation Research · doi:10.1161/circresaha.112.280958 · Cited by 70
“%) in the CCHS population, were not associated with decreased risk of MI.10 In addition to the consistency among these Mendelian randomization studies, the results in Voight et al are further strengthened by their data on the HDL-C genetic score composed of 14 common SNPs in the study population, which as noted above…”
ResultInfluentialNordestgaard, B. G., & Tybjærg-Hansen, A. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834477d2 · Cited by 67
Self-citationKjeldsen, E. W., Thomassen, J. Q., & Frikke‐Schmidt, R. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159063 · Cited by 77
Self-citationNordestgaard, L. T., Christoffersen, M., Lauridsen, B. K., Afzal, S., Nordestgaard, B. G., Frikke-Schmidt, R., & Tybjærg-Hansen, A. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2021.3728 · Cited by 61
Self-citationTietjen, I., Hovingh, G. K., Singaraja, R., Radomski, C., McEwen, J., Chan, E., Mattice, M., Legendre, A., Kastelein, J. J. P., & Hayden, M. R. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.08.006 · Cited by 58
Human genetics of HDL: Insight into particle metabolism and function
Brunham, L. R., & Hayden, M. R. (2015) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.01.001 · Cited by 53
Li, X., Guan, B., Wang, Y., Tse, G., Zou, F., Waleed, K. B., Xia, Y., Wu, S., & Sun, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-50924-4 · Cited by 49
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I. M., Backer, G. D., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0157 · Cited by 62
Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219827620 · Cited by 38
“sequenced the regulatory and coding regions of APOA1 in 190 individuals from the Copenhagen City Heart Study with the lowest 1% (n1⁄4 95) and highest 1% (n1⁄4 95) apoA-I concentrations.(145) Genotype combinations of two SNPs were associated with increases in apoA-I and HDL-C concentrations of up to 6.”
BackgroundMendelian randomization reveals unexpected effects of CETP on the lipoprotein profile
Blauw, L. L., Noordam, R., Soidinsalo, S., Blauw, C. A., Li‐Gao, R., de Mutsert, R., Berbée, J. F. P., Wang, Y., van Heemst, D., Rosendaal, F. R., et al. (2018) · European Journal of Human Genetics · doi:10.1038/s41431-018-0301-5 · Cited by 40
HDL, cholesterol efflux, and ABCA1: Free from good and evil dualism
Ogura, M. (2022) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2022.07.004 · Cited by 47
Haase, C. L., Frikke‐Schmidt, R., Nordestgaard, B. G., Kateifides, A. K., Kardassis, D., Nielsen, L. B., Andersen, C. B., Køber, L., Johnsen, A., Grande, P., et al. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02381.x · Cited by 38
Self-citationHaase, C. L., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1003063 · Cited by 37
“1 mmol/L in the 1% of individuals heterozygous for both variants [12].”
BackgroundMethodSelf-citationChristensen, J. J., Ulven, S. M., Retterstøl, K., Narverud, I., Bogsrud, M. P., Henriksen, T., Bollerslev, J., Halvorsen, B. L., Aukrust, P., & Holven, K. B. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.09.021 · Cited by 37
HDL and Atherothrombotic Vascular Disease
Annema, W., von Eckardstein, A., & Kovanen, P. T. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-09665-0_11 · Cited by 36
“Likewise, genetic variation in the apolipoprotein A-I (apoA-I) gene, APOA1, affecting apoA-I and HDL cholesterol levels did not predict ischemic heart disease or myocardial infarction in the general population (Haase et al. 2010).”
BackgroundVrins, C. L. J., Out, R., van Santbrink, P. J., van der Zee, A., Mahmoudi, T., Groenendijk, M., Havekes, L. M., van Berkel, T. J. C., van Dijk, K. W., & Biessen, E. A. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057492 · Cited by 33
“[6–10].”
Wang, Z., Chen, T., Wu, S., Dong, X., Zhang, M., & Ma, G. (2024) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.04.021 · Cited by 42
Mendelian randomisation, lipids, and cardiovascular disease
Harrison, S. C., Holmes, M. V., & Humphries, S. E. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60481-4 · Cited by 33
Abdel‐Razek, O., Sadananda, S. N., Li, X., Cermakova, L., Frohlich, J. J., & Brunham, L. R. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.10.010 · Cited by 30
Mendelian randomization: Its impact on cardiovascular disease
Kawashiri, M., Tada, H., Nomura, A., & Yamagishi, M. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.04.007 · Cited by 29
Clinical Perspectives of Genetic Analyses on Dyslipidemia and Coronary Artery Disease
Tada, H., Kawashiri, M., & Yamagishi, M. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17002 · Cited by 30
Egom, E. E. A., Mamas, M. A., & Soran, H. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328361f822 · Cited by 31
“Consistently, early Mendelian randomized analyses found that genetically increased HDL-C levels were not associated with a decreased cardiovascular risk [23,24].”
BackgroundWang, X., He, J., Guo, H., Mu, L., Hu, Y., Ma, J., Yan, Y., Ma, R., Li, S., Ding, Y., et al. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0581-8 · Cited by 25
“conducted a molecular analysis of the APOA1 gene found that rs670 was associated with increased HDL-C [38], however, S.”
BackgroundChi, G., Lee, J., Kazmi, S. H. A., Fitzgerald, C., Montazerin, S. M., Kalaycı, A., Korjian, S., Heise, M. A., Deckelbaum, L. I., Libby, P., et al. (2022) · Clinical Cardiology · doi:10.1002/clc.23773 · Cited by 27
Serum creatinine is associated with coronary disease risk even in the absence of metabolic disorders
Onat, A., Yüksel, H., Can, G., Köroğlu, B., Kaya, A., & Altay, S. (2013) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2013.821712 · Cited by 25
Rosales, C., Gillard, B. K., Xu, B., Gotto, A. M., & Pownall, H. J. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-1-47 · Cited by 26
Frikke‐Schmidt, R. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.03.005 · Cited by 23
Self-citationModified and Dysfunctional Lipoproteins in Atherosclerosis: Effectors or Biomarkers?
Orekhov, A. N., & Sobenin, I. A. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180320121137 · Cited by 23
Al‐Bustan, S. A., Al‐Serri, A., Annice, B. G., Alnaqeeb, M. A., & Ebrahim, G. A. (2013) · BMC Medical Genetics · doi:10.1186/1471-2350-14-90 · Cited by 26
“[19] conducted a molecular analysis of the APOAI gene locus in over 10000 Danish individuals and reported a positive association between the APOAI −75 polymorphism and LDL and TC levels, and that homozygosity of APOAI rs670 A and heterozygosity of the APOAI rs5069 polymorphism were associated with increased HDL-C and…”
BackgroundMethodResultInfluentialChroni, A., & Kardassis, D. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180313114950 · Cited by 24
High-density lipoprotein cholesterol concentration and acute kidney injury after noncardiac surgery
Zhou, Y., Yang, H., Zhang, H., & Zhu, X.-J. (2020) · BMC Nephrology · doi:10.1186/s12882-020-01808-7 · Cited by 23
Khoury, P. E., Ghislain, M., Villard, E. F., Goff, W. L., Lascoux‐Combe, C., Yéni, P., Meyer, L., Vigouroux, C., Goujard, C., & Guérin, M. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m054510 · Cited by 21
Genetic Polymorphisms in the APOA1 Gene and their Relationship with Serum HDL Cholesterol Levels
Bandarian, F., Hedayati, M., DANESHPOUR, M. S., Naseri, M., & Azizi, F. (2013) · Lipids · doi:10.1007/s11745-013-3847-6 · Cited by 19
“Previous resequencing studies in individuals with two extremes of HDL-C levels have shown large variability in mutation frequencies for this gene [17–19].”
BackgroundTada, H., Kawashiri, M., & Yamagishi, M. (2017) · Journal of Human Genetics · doi:10.1038/jhg.2016.159 · Cited by 19
Magnoni, M., Andreini, D., Pirillo, A., Uboldi, P., Latini, R., Catapano, A. L., Maggioni, A. P., Norata, G. D., & on behalf of the CAPIRE Study Group (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2063374 · Cited by 18
Lusk, C. M., Dyson, G. E., Clark, A. G., Ballantyne, C. M., Frikke‐Schmidt, R., Tybjærg‐Hansen, A., Boerwinkle, E., & Sing, C. F. (2014) · Human Genetics · doi:10.1007/s00439-014-1451-3 · Cited by 17
Self-citationNew Insights into the High-Density Lipoprotein Dilemma
Pownall, H. J., & Gotto, A. M. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.11.004 · Cited by 23
“For example, some patients with genetically elevated plasma levels of apolipoprotein AI (apo AI), the major protein component of HDL, and HDL-C, did not have a reduced risk for ischemic heart disease or MI[12]; an HDL-C– raising endothelial lipase variant was not associated with reduced MI [13]; controlling for Pownal…”
BackgroundZhang, Q., Ke, Y., & Hong, H. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-1592-5_4 · Cited by 21
Nazari, S. S. H., Shakiba, M., Khalili, D., Hadaegh, F., Tohidi, M., & Azizi, F. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.04.001 · Cited by 14
The Alcohol–High-Density Lipoprotein Athero-Protective Axis
Rosales, C., Gillard, B. K., Gotto, A. M., & Pownall, H. J. (2020) · Biomolecules · doi:10.3390/biom10070987 · Cited by 16
“[9] (4) Loss-of-function variants that raise (endothelial lipase) [10] or lower (adenosine triphosphate (ATP) binding cassette transporter subfamily A member 1 (ABCA1)) [9] HDL-C levels are not associated with reduced or increased ASCVD risk, respectively [9].”
BackgroundInheritance of high and low HDL: mechanisms and management
Sourlas, A., & Kosmas, C. E. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000610 · Cited by 13
“There is a controversy in the literature whether upregulation of ApoA-I is associated with increased or decreased CVD risk, as studies have shown contradictory results [25,26].”
ResultFunctional impact of bioactive peptides derived from fermented foods on diverse human populations
Bhattacharjee, M. J., Bala, A., Khan, M. R., & Mukherjee, A. K. (2025) · Food Chemistry · doi:10.1016/j.foodchem.2025.145416 · Cited by 20
HDL as a Causal Factor in Atherosclerosis: Insights from Human Genetics
Brunham, L. R. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0623-0 · Cited by 12
Onat, A., Can, G., Örnek, E., Ayhan, E., Erginel‐Ünaltuna, N., & Murat, S. N. (2012) · Lipids · doi:10.1007/s11745-012-3724-8 · Cited by 12
Cholesterol: Can’t Live With It, Can’t Live Without It
Pownall, H. J., & Gotto, A. M. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-1-9 · Cited by 11
Cheema, A. N., Pirim, D., Wang, X., Ali, J., Bhatti, A., John, P. C. L., Feingold, E., Demirci, F. Y., & Kamboh, M. I. (2020) · Disease Markers · doi:10.1155/2020/9738567 · Cited by 11
“Additionally, PLG has been shown to be part of one of four CAD risk loci (APOA1, MRAS, IL6R, and PLG) that are involved in the acute inflammatory response signaling pathway [26].”
BackgroundLDL, HDL, VLDL, and CVD Prevention: Lessons from Genetics?
Hewing, B., & Landmesser, U. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0610-z · Cited by 13
Trius‐Soler, M., Mukamal, K. J., & Guasch‐Ferré, M. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000906 · Cited by 10
Khalil, H. S., Murrin, C. M., O'Reilly, M. E., Viljoen, K., Segurado, R., O’Brien, J., Somerville, R. L., McGillicuddy, F. C., & Kelleher, C. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.10.002 · Cited by 12
Targeting HDL-cholesterol to reduce residual cardiovascular risk
Iacob, A. O., & Choudhury, R. P. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32835135bd · Cited by 7
Inoue, H., Shiga, Y., Norimatsu, K., Tashiro, K., Futami, M., Suematsu, Y., Sugihara, M., Nishikawa, H., Katsuda, Y., & Miura, S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112431 · Cited by 7
Kronenberg, F. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02403.x · Cited by 6
Fu, L., Liu, Q., Cheng, H., Zhao, X., Xiong, J., & Mi, J. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038857 · Cited by 6
“16,17 The previous studies 18–22 have some shortcomings: (1) most of the mentioned studies are focused on ischemic heart diseases, CHD, and type 2 diabetes, and it is not known what impacts lipids and lipid-targeting drugs have on other cardiometabolic conditions; (2) lipid-drug targets influence…”
High-Density Lipoprotein Processing and Premature Cardiovascular Disease
Rosales, C., Gillard, B. K., Gotto, A. M., & Pownall, H. J. (2015) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-11-3-181 · Cited by 8
Gorshkova, I. N., Meyers, N. L., Herscovitz, H., Mei, X., & Atkinson, D. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100319 · Cited by 4
“tions that are associated with either both reduced plasma HDL-C and reduced apoA-I levels (8, 10, 40–42) or elevated HDL-C along with elevated plasma apoA-I levels (40).”
BackgroundHuman Plasma Lipoprotein Metabolism
Pownall, H. J., Rosales, C., Gillard, B. K., Moon, J. E., & Gotto, A. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00001-3 · Cited by 7
Paré, G., Mao, S., & Deng, W. Q. (2018) · Genetic Epidemiology · doi:10.1002/gepi.22149 · Cited by 4
Variations in high density cholesterol levels based on apolipoprotein E variant and exercise type
Chang, C.-M., Nfor, O. N., Ho, C., Chen, P.-H., & Liaw, Y. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1136483 · Cited by 3
“Several variants of these genes have been associated with HDL cholesterol (Haase et al., 2010; Haase et al., 2012; Voight et al., 2012).”
BackgroundThe unresolved mystery of high-density lipoprotein: time for a paradigm shift?
Enkhmaa, B., Anuurad, E., & Berglund, L. (2016) · Translational research · doi:10.1016/j.trsl.2016.03.004 · Cited by 3
Pathogenesis of atherosclerosis: lipid metabolism
Wiklund, O., & Borén, J. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198755777.003.0011 · Cited by 3
High‐Density Lipoprotein Therapies—Then and Now
Pownall, H. J., Rosales, C., Gillard, B. K., & Gotto, A. M. (2015) · Wiley eBooks · doi:10.1002/9781118828533.ch42 · Cited by 3
Maleki, M., & Hosseini, Z. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-80915-3.00012-0 · Cited by 1
The Impact of Plant-Based Diets on Cardiovascular Disease and Its Risk Factors
Allen, K., Bassin, S. R., & Ostfeld, R. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-63083-5_26 · Cited by 1
Prevention and Treatment of Atherosclerotic Vascular Disease: Hypolipidemic Agents
Gotto, A. M., & Pownall, H. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-15961-4_28 · Cited by 1
“In the Copenhagen City Heart Study, patients with genetically elevated plasma levels of apo AI and HDL-C did not have a reduced risk for ischemic heart disease or myocardial infarction [ 47 ].”
BackgroundBeleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
Klose, G., & Hambrecht, R. (2013) · Der Kardiologe · doi:10.1007/s12181-013-0505-4
Toth, P. P. (2012) · Yearbook of Endocrinology · doi:10.1016/j.yend.2012.05.033
Toth, P. P. (2011) · Yearbook of Endocrinology · doi:10.1016/j.yend.2011.06.076
Mendelian randomisation, lipids, and cardiovascular disease
Voight, B. F. (2012)
Paré, G., Mao, S., & Deng, W. Q. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/143644
Maleki, M., & Hosseini, Z. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-51149-0.00016-x
(2018) · Wiley eBooks · doi:10.1002/9781118829875.refs
Kontush, A., & Chapman, M. J. (2011) · Wiley eBooks · doi:10.1002/9781118158678.ch6
Shek, A. B., Alieva, R. B., Abdullaev, A. A., Fozilov, K. G., Hoshimov, S. U., Матсапаевна, Б. Ф., Nizamov, U. I., & Ziyaeva, A. V. (2022) · International Journal of Biomedicine · doi:10.21103/article12(2)_oa1 · Cited by 1
Passarelli, M., Yokoyama, S., & Sposito, A. C. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.963463
“, 2017) and also after observational studies with Mendelian randomization which failed in demonstrating the association between increased HDLcholesterol or apo A-I and CVD outcomes (Frikke-Schmidt et al., 2008; Johannsen et al., 2009; Haase et al., 2010; Voight et al., 2012).”
BackgroundRahajoe, T., Nugraheni, K., Widiyani, P. A., Asihanto, B. A. P., & Kartika, A. I. (2023) · JURNAL INFO KESEHATAN · doi:10.31965/infokes.vol21.iss4.1222
“Sequence variations and allelic frequencies in the APOA-1 promoter region can influence variations in APOA-1 expression (França, Alves, & Hutz, 2005; Haase, et al., 2010; Wang, et al., 2017) which will affect the amount of lipids in serum The change in amino acid sequence from guanine to adenine at…”
BackgroundApolipoproteins and cardiovascular diseases
Kaur, A., Saha, S., Ujjainiya, R., Ray, A., Basak, T., & Sengupta, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19116-9.00032-4
Metadata
- Authors
- Haase, C. L., Tybjærg-Hansen, A., Grande, P., & Frikke-Schmidt, R.
- Affiliations
- University of Copenhagen (DK)
- ORCID
- Haase, Christiane L.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2010-12
- Volume
- 95
- Issue
- 12
- Pages
- E500-E510
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2074535217
- Cited by
- 104
- References
- 39
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 8 · 2021: 8 · 2020: 6 · 2019: 6 · 2018: 7 · 2017: 8 · 2016: 9 · 2015: 11 · 2014: 4 · 2013: 10 · 2012: 9
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- apolipoprotein A-I, HDL cholesterol, ischemic heart disease, myocardial infarction, genetic variants, single nucleotide polymorphisms, haplotypes, genetic association, cardiovascular risk, promoter polymorphism
- MeSH terms
- Aged, Chromosomes, Human, Pair 11, Denmark, DNA, Family, Female, Gene Expression Regulation, Genotype, Humans, Cholesterol, HDL, Male, Middle Aged, Phenotype, Genetic Variation, Apolipoprotein A-I, Myocardial Ischemia, Twin Studies as Topic, Risk Assessment, Polymorphism, Single Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.